August 10, 2026

By E-mail

Matt McLaughlin

Comscore, Inc.

11950 Democracy Drive

Suite 600

Reston, VA 20190

Dear Matt:

This letter (this “Agreement”) modifies the letter agreement, dated May 28, 2026, between you and the Company (the “CEO Letter”). Upon execution of this Agreement by you and the Company, the CEO Letter will be deemed amended to reflect the following terms, which will govern your continued employment with the Company.

1.Base Salary Reduction. Effective October 1, 2026, your base salary will be reduced by 20% such that, as of such date, your annualized base salary will be $500,000 for the remainder of 2026 and $515,000 for 2027. Your base salary will continue to be paid semi-monthly (on the 15thand last day of each month) in accordance with Comscore’s standard payroll practices and subject to applicable payroll deductions and withholdings. By signing this Agreement, you are agreeing to this salary reduction and are waiving any notice period that may be required by your state of residence and/or employment. Your annualized base salary will revert to no less than $663,063 (your current salary plus annual escalators per the CEO Letter) effective January 1, 2028.

…

Achieve Life Sciences, Inc.

Employment Agreement

This Employment Agreement (this “Agreement”) is entered into by and between Andrew D. Goldberg, MD (the “Executive”) and Achieve Life Sciences, Inc., a Delaware corporation (the “Employer” or the “Company”) as of April 16, 2026 (the “Effective Date”). The terms of the Executive’s employment with the Company (“Employment” and commencement thereof, the “Start Date”) are set forth in this Agreement. Defined terms used in this Agreement, and not defined in line, are set forth in Section 7.

1.

Duties and Scope of Employment.

The Employer agrees to employ the Executive in the position of Chief Executive Officer (“CEO”), reporting directly to the Company’s Board of Directors (the “Board”). The Executive shall have such duties, authority and responsibilities that are commensurate with the position of CEO.

The Executive will be appointed to the Board effective on or before the Start Date, and for so long as Executive serves as the CEO, subject to the requirements of applicable law (including, without limitation, any rules or regulations of any exchange on which the common stock of the Company is listed), the Board and/or a committee of the Board will nominate Executive for re-election to the Board at each annual meeting at which Executive is subject to re-election. If Executive’s position as CEO is terminated by Executive or the Company for any reason, Executive agrees to promptly resign from the Board and any committee thereof, unless requested otherwise by the Board (the “Resignation Requirement”).

…

DATED 08 May 2026

(1) ACHIEVE PHARMA UK LIMITED

(2) ACHIEVE LIFE SCIENCES, INC.

(3) RICHARD STEWART

SETTLEMENT AGREEMENT

WITHOUT PREJUDICE AND SUBJECT TO CONTRACT

---

THISAGREEMENTis made on 08 May 2026

BETWEEN:-

(1) ACHIEVE PHARMA UK LIMITED(company number 06751116) whose registered office is at 10 Station Road, Henley-On-Thames, Oxfordshire, RG9 1AY (the "Company");

(2) ACHIEVE LIFE SCIENCES, INC.whose registered office is at 22722 29th Dr. SE Suite 100, Bothell, WA, 98021 (the "Achieve Inc."); and

(3) RICHARD STEWARTof (the "Executive").

WHEREAS:-

(A)

The Executive is employed by the Company as Chairman and Chief Executive Officer of the Company and Chief Executive Officer of Achieve Inc. pursuant to a contract between the Executive and the Company dated 9 May 2025 as amended or varied from time to time (the "Service Agreement").

(B)

Pursuant to the terms of this Agreement, the parties have agreed that the Executive's employment by the Company and appointment as Chairman and Chief Executive Officer of the Company will terminate on the date of this Agreement (the "Termination Date"). The Executive's directorship of the Company shall end on the Termination Date. The Executive’s appointment as Chief Executive Officer of Achieve Inc., terminated on 17 April 2026.

(C)

…

August 5, 2026

David Rodman, M.D.

Re:    Amendment to Employment Letter Agreement

Dear Dr. Rodman:

This is an amendment (this “Amendment”) to the existing amended and restated employment letter agreement dated February 1, 2023 (the “Letter Agreement”), between you and Mineralys Therapeutics, Inc. (the “Company”). The Company is amending the Letter Agreement to provide that, effective asof August 10, 2026, you shall continue your employment with the Company in a non-executive capacity as a Strategic Advisor and shall perform such duties as are customarily associated with such position and such other duties as are assigned to you by your supervisor, the Company’s Chief Executive Officer. Your job duties and responsibilities may change from time to time, without advance notice, in the sole discretion of the Company. Your employment with the Company will continue to be “at-will” at all times.

Except as specifically set forth in this Amendment, all of the remaining terms of the Letter Agreement shall remain unchanged and in full force and effect. For the avoidance of doubt, you acknowledge and agree that you consent and agree to the terms and conditions of this Amendment, and that nothing contained herein shall constitute, give rise to or be deemed to constitute or give rise to Good Reason for purposes of the Letter Agreement or any other compensatory agreement to which you are a party with the Company.

…

EXECUTIONVERSION

OMNIBUSAMENDMENTTOLOAN,SECURITYANDCOLLATERAL MANAGEMENT AGREEMENT, dated as of May 4, 2026 (this “Amendment”), amongPhillip Street Middle Market Lending Investments LLC, as the borrower (the “Borrower”), PhillipStreet BDC LLC, as thecollateral manager(the“Collateral Manager”), and Ally Bank, as the arranger (the “Arranger”), as the administrative agent (the “Administrative Agent”) and asthe swingline lender (the “Swingline Lender”).

WHEREAS, the Borrower, the Collateral Manager, the Arranger, the Swingline Lender, the other Lenders from time to time parties thereto, the Administrative Agent, Phillip Street BDC LLC, as the transferor, Phillip Street Middle Market Lending Investment Holdings LLC, as the equityholder and State Street Bank and Trust Company, as the collateral custodian, are party to the Loan, Security and Collateral Management Agreement, dated as of February 10, 2023 (as may be amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”);

WHEREAS, the Collateral Manager, Fund and Transferor has changed its name from Phillip Street Middle Market Lending Fund LLC to Phillip Street BDC LLC;

WHEREAS, the parties hereto desire to amend the Loan Agreement inaccordance with Section 12.1 of the Loan Agreement and subject to the terms and conditions set forth herein; and

…

***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) of the type that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (“[…***…]”) in this exhibit.***

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 8, 2026 and made effective as of June 30, 2026 (the “First Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and KYVERNA THERAPEUTICS, INC., a Delaware corporation with offices located at 5980 Horton St., Suite 200, Emeryville, CA 94068 (“Borrower”).

WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of October 31, 2025 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and

…

April 13, 2026

Nadia Dac
via email to […***….]

Re:Employment Terms

Dear Nadia:

Kyverna Therapeutics, Inc. (the “Company”) is pleased to offer you employment beginning on May 4, 2026 (the “Start Date”); provided, however, if your employment does not commence on the Start Date, this letter shall be null and void and without force or effect.

Position

Your position will be Chief Commercial Officer of the Company with responsibilities, duties, and authority as usual and customary for such position, reporting to the Company’s Chief Executive Officer and Executive Chairperson of the Board of Directors (the “Board”). In this position, you will be permitted to work remotely, subject to reasonable business travel. The Company may change your position, duties, and work location from time to time in its discretion, subject to the severance protections outlined below.

While you are employed by the Company, you will (i) devote your full business time, energy and skill to the performance of your duties for the Company and (ii) hold no other employment or consulting positions, unless you receive written consent from the Board in advance. Notwithstanding the foregoing, you shall be entitled to engage in (a) service on the board of directors of two for-profit companies, businesses or trade organizations, provided that you shall not serve on the board of any entity that competes with the Company, as determined by the Board, (b) service on the board of directors of not-for-profit organizations, (c) other charitable activities and community affairs, and (d) management of your

…

---

Exhibit 10.3

NOTICE OF GRANT

CASH INCENTIVE UNITS

ANTERIS TECHNOLOGIES GLOBAL CORP. EQUITY INCENTIVE PLAN

(AUSTRALIA SERVICE PROVIDER)

Anteris Technologies Global Corp., a Delaware corporation (the “Company”), has awarded to Participant, as identified below, the number of cash incentive units (the “Units”, and each such unit, an “Unit”) set forth below. The Units are subject to all of the terms and conditions as set forth in this Notice of Grant (this “Notice”) as well as in the Company’s Equity Incentive Plan (the “Plan”) and the Service Provider Cash Incentive Unit Agreement (the “Agreement”), both of which are attached hereto and incorporated in their entirety. For purposes of clarity, the Units shall constitute an “other award” within the meaning of Section 9 of the Plan and shall be settled exclusively in cash. Capitalized terms not explicitly defined in this Notice but defined in the Plan or the Agreement will have the same definitions as in the Plan or the Agreement. In the event of any conflict between the terms of the Award and the Plan, the terms of the Plan will control.

…

CONSULTING SERVICES AGREEMENT

THIS AGREEMENT(the “Agreement”) is made effective as of July 15, 2026 (the “Effective Date”) by and between SAVARA INC., a Delaware corporation having a principal place of business at One Summit Square, 1717 Langhorne Newtown Rd., Suite 300, Langhorne, PA 19047 (“Savara”), and David Lowrance, an individual having a principal place of business at [redacted] (“Consultant”).

BACKGROUND:

A.Savara is a pharmaceutical development company engaged in the business of developing and commercializing biotechnology and pharmaceutical products with a focus on pulmonary diseases (the “Field”).

B.Consultant has expertise relevant to Savara’s work in the Field.

C.Savara now desires to engage Consultant to provide services on and subject to the terms and conditions set forth in this Agreement.

NOW, THEREFORE,intending to be legally bound, the parties agree as follows:

1. Consulting Services.

1.1. Consultant will provide the services described on the attached Schedule A(the “Services”) to Savara or its affiliates.

1.2. When providing the Services, Consultant will comply with Savara’s policies, standards, rules, and regulations, as they may exist from time to time. Consultant will perform the Services to the best of its abilities and in a diligent, trustworthy, businesslike, and efficient manner, exercising due care in the performance of Services and rendering them in accordance with prevailing professional standards and ethics.

…

CHANGE IN CONTROL AGREEMENT

This Change in Control Agreement (the “Agreement”) is entered into as of the 7th day of August 2026, by and between SINTX Technologies, Inc., together with its successors and assigns, the “Company”, and Kevin Trask, the Company’s Chief Financial Officer, (the “Executive”).

WHEREAS, the Executive is the Chief Financial Officer of the Company;

WHEREAS, the Company recognizes that the Executive’s service to the Company is very important to the future success of the Company;

WHEREAS, Executive desires to enter into this Agreement to provide Executive with certain financial protection in the event Executive’s employment terminates under specified circumstances in connection with a Change in Control of the Company; and

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to enter into this Agreement.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive agree as follows:

1. Definitions.

…

AMENDMENT NO. 1

TO THE

ANAPTYSBIO, INC.

AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN

August 11, 2026

This Amendment No. 1 (this “Amendment”) to the AnaptysBio, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”) was approved and adopted by the Board of Directors (the “Board”) of AnaptysBio, Inc. (the “Company”) on the date first written above, and will be effective as of the date on which this Amendment is approved by the stockholders of the Company (the “Amendment Effective Date”).

WHEREAS, the Company maintains the Plan, and pursuant to Section 24 of the Plan, the Board is authorized to amend the Plan;

WHEREAS, the Board desires to amend the Plan to (i) extend the term of the Plan for ten (10) years from the date this Amendment is approved by the Board and (ii) update the yearly non-employee director compensation limitations; and

WHEREAS, following approval by the Board, this Amendment will become effective as of and contingent upon approval by the Company’s stockholders and if, for any reason, the Company’s stockholders fail to approve this Amendment, this Amendment shall be void ab initioand the existing Plan shall continue in full force and effect.

NOW, THEREFORE, the Plan is hereby amended as follows, subject to and effective upon the Amendment Effective Date:

1.

Capitalized Terms. Capitalized terms that are not defined in this Amendment shall have the meanings ascribed thereto in the Plan.

2.

Amendments to the Plan.

2.1.

…

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement,” as the same may hereafter be modified, supplemented, extended, amended, restated, or amended and restated from time to time), is entered into and made effective as of August 8, 2026 (the “Effective Date”), by and among CHAINCE DIGITAL HOLDINGS INC., an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the “Company”), and certain purchasers each executing this Agreement separately and whose name and investment details are set forth on the signature pages hereto (each an “Purchaser” and collectively, the “Purchasers”). 

RECITALS

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective Registration Statement (defined below) under the Securities Act of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

WHEREAS, the Company desires to issue and sell to each Purchaser, and each Purchaser, desires to purchase from the Company, with each Purchaser’s investment amount set out on the signature page hereto by each Purchaser in this Agreement, up to an aggregate of 30,560,000 ordinary shares (the “Shares”), par value $0.004 per share, of the Company (“Ordinary Shares”, each “Ordinary Share”), in accordance with the terms and conditions of this Agreement.

AGREEMENT

…